DC22396 |
LSD1 inhibitor-1 |
LSD1 inhibitor-1 is a bisguanidine polyamine analogue that exhibits noncompetitive and specific LSD1 inhibition, with 14.1% remaining LSD1 activity at 10 uM in vitro. |
|
DC8541 |
ORY-1001(Ladademstat)
Featured
|
ORY-1001 dihydrochloride (RG-6016, Ladademstat) is a highly potent, selective inhibitor of lysine-specific demethylase KDM1A (LSD1) with IC50 of 18 nM, displays high selectivity for KDM1A over other FAD-containing monoamine oxidases. |
|
DC23384 |
LSD1-IN-11p |
LSD1-IN-11p is a reversible LSD1 inhibitor with IC50/Kd of 79/21 nM. |
|
DC23379 |
LSD1-IN-32 |
LSD1-IN-32 is a potent, reversible lysine specific demethylase 1 (LSD1) inhibitor with biochemical IC50 of 83 nM, Kd of 32 nM, cell EC50 of 0.67 uM. |
|
DC8698 |
L-SelenoMethionine |
L-SelenoMethionine is a major natural food-form of selenium. |
|
DC21249 |
LSN 3213128
Featured
|
LSN 3213128 is a novel potent, selective and orally-bioavailable antifolate with potent and specific inhibitory activity for AICARFT. |
|
DC7878 |
LSN2814617
Featured
|
LSN2814617 is a neurotoxic positive allosteric modulator. |
|
DC10665 |
LSN3154567(Nampt-IN-1)
Featured
|
LSN3154567 is a novel inhibitor of NAMPT with IC50 of 18 nM (NCI-H1155 cell), 49 nM (Calu-6 cell), 333 nM (HCC1937 cell), and 389 nM (MCF-7 cell), respectively. |
|
DC23503 |
LSP1-2111 |
LSP1-2111 is a potent, selective, and brain penetrant group III mGluRs agonist with EC50 of 2.2 and 1.7 uM for mGluR4 and mGluR6, respectively. |
|
DC26113 |
LSP4–2022
Featured
|
LSP4–2022 is a novel potent, selective, brain-penetrant mGluR4 agonist with EC50 of 0.11 uM in cell-based assays. |
|
DC10755 |
LSZ-102
Featured
|
LSZ102 is a potent, orally bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer. |
|
DCAPI1211 |
L-Thyroxine |
L-Thyroxine |
|
DC10072 |
LTI-291
Featured
|
LTI-291 is a Glucocerebrosidase (Gcase) activator for the treament of Parkinson's disease (PD). |
|
DC10155 |
LTURM34 |
LTURM34 is a specific DNA-PK inhibitor with an IC50 of 0.034 μM. |
|
DC24031 |
LTV-1 |
LTV-1 is a highly potent, cell-permeable and reversible LYP (lymphoid tyrosine phosphatase) inhibitor with IC50 of 508 nM. |
|
DC10987 |
LTX-315 |
This product is discontinued. LTX-315 (Oncopore) is a synthetic 9-mer anticancer peptide that preferentially permeabilizes mitochondrial membranes, thereby causing partially BAX/BAK1-regulated, caspase-independent necrosis. |
|
DC10988 |
LTX-401
Featured
|
LTX-401 is a novel oncolytic amino acid derivative that specifically targets the Golgi apparatus, demonstrating significant potential in cancer therapy. In vitro studies reveal that LTX-401 effectively reduces the viability of various tumor cell lines, exhibiting cytotoxic activity across a range of concentrations. Notably, it shows the highest potency against the human malignant melanoma cell line MDA-MB-435S (IC50 = 13.5 μM) and the lowest activity against the human hepatocellular carcinoma cell line HEPG2 (IC50 = 35.4 μM). For other cell lines, the IC50 values fall within a narrow range of 19-32 μM. Importantly, LTX-401 does not induce hemolysis in red blood cells at concentrations effective for cancer cell death, with hemolytic activity only observed at much higher concentrations (400 μg/mL = 1087 μM). Additionally, LTX-401 demonstrates cytotoxicity against non-malignant cell lines, including HUV-EC-C endothelial cells, HaCat keratinocytes, and MRC-5 fibroblasts, suggesting a broad but selective mechanism of action. |
|
DC7583 |
Idalopirdine(Lu-AE-58054)
Featured
|
Lu AE58054 is an in-vitro potency and selectivity, in-vivo binding affinity and effect of the 5-HT(6)R antagonist with a Ki value of 0.83 nM. |
|
DC9784 |
Lu AF21934
Featured
|
Lu AF21934 is a brain-penetrating positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu4),reduces the harmaline-induced hyperactivity |
|
DC8287 |
Lubiprostone
Featured
|
Lubiprostone(SPI-0211;RU0211) is a gastrointestinal agent used for the treatment of idiopathic chronic constipation. |
|
DC7170 |
Lucidin (NSC 30546) |
Lucidin (NSC 30546) is a natural component of Rubia tinctorum L. lucidin is mutagenic in bacteria and mammalian cells. |
|
DC22596 |
LUF6000 |
LUF6000 is a potent, selective, positive allosteric modulator (enhancer) of human A3 adenosine receptor, enhance Emax but without affecting agonist potency. |
|
DC23647 |
LUF7346
Featured
|
LUF7346 is a novel hERG allosteric modulator that slows IKr deactivation and positively shifting IKr inactivation. |
|
DC8611 |
Luliconazole
Featured
|
Luliconazole(NND 502) is an azole antifungal indicated for the topical treatment of interdigital tinea pedis. |
|
DC22906 |
Lumateperone
Featured
|
Lumateperone (ITI-007) is a potent 5-HT2A antagonist (Ki=0.54 nM), postsynaptic D2 antagonist(Ki=32 nM), and SERT blocker (Ki= 61 nM). |
|
DC11422 |
Lumateperone Tosylate
Featured
|
Lumateperone Tosylate is a 5-HT2A receptor antagonist (Ki = 0.54 nM), a partial agonist of presynaptic D2 receptors and an antagonist of postsynaptic D2 receptors (Ki = 32 nM), and a SERT blocker (Ki = 61 nM). |
|
DCAPI1570 |
Hydroxychloroquine Sulphate |
Lupus erythematosus suppressant as well as an antimalerial and antirheumatic. |
|
DC3173 |
Lurasidone HCl
Featured
|
Lurasidone is an atypical antipsychotic, inhibits Dopamine D2, 5-HT2A, 5-HT7, 5-HT1A and noradrenaline α2C with IC50 of 1.68 nM, 2.03 nM, 0.495 nM, 6.75 nM and 10.8 nM, respectively. |
|
DC3174 |
lurasidone |
Lurasidone is a novel psychotropic agent that has been shown in studies of cloned human receptors to be an antagonist at the 5-HT2A receptor. |
|
DC9938 |
Lusutrombopag(S-888711)
Featured
|
Lusutrombopag(S-888711) is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist being developed by Shionogi for chronic liver disease (CLD) patients with thrombocytopenia prior to elective invasive surgery. |
|